The best part of trading starts at 9:30am EST

The deal was already two months old. Nobody moved on it in August. Then Thursday morning, a single 8-K filing changed the math entirely, and Haemonetics shares closed about 16% higher on the day.

What Actually Changed

When Haemonetics first disclosed its supply agreement with CSL Plasma on August 18, the language was cautious. CSL may utilize NexSys PCS devices and purchase related disposables. The scope and timing were undecided. Haemonetics did not update its fiscal 2027 guidance. Wall Street noted the deal and mostly moved on.

October 8 was different. CSL told Haemonetics it now expects the transition to occur at all of its current U.S. plasma collection centers, with the full rollout targeted by the end of calendar 2027. That is 300-plus facilities. “Partial” became “complete.” Ambiguous became scheduled. The stock responded accordingly.

Why Disposables Are the Real Prize

Haemonetics does not simply sell machines. It sells the consumable kits used in every collection procedure, and those kits replenish on a per-donation basis. A plasma center that runs hundreds of donors per day is a recurring revenue engine, not a one-time equipment sale. Across 300-plus CSL centers, that disposable stream could be substantial.

Analysts had already framed the revenue potential. Before Thursday’s update, Needham & Co. projected that a full CSL transition could eventually add between $183 million and $223 million in annual revenue to Haemonetics, assuming a pricing premium for the NexSys platform’s newer Persona PLUS technology. Persona PLUS, which received FDA clearance in February 2026, delivers on average a mid-single-digit percentage increase in plasma yield per donation over Persona. That yield improvement is the commercial argument CSL is evidently buying.

The Context That Makes the Move Make Sense

This is not a new customer. It is a returning one, and the gap years matter. CSL’s contract with Haemonetics expired in mid-2022 and was not renewed. In the interim, CSL equipped its entire U.S. network with Terumo’s Rika systems, with CSL and Terumo announcing the nationwide U.S. rollout was completed in September 2025.

Now the trajectory reverses. Haemonetics posted Q1 fiscal 2027 revenue of $339.4 million, up 5.6% year-over-year and ahead of consensus estimates that clustered around the high-$320 millions to roughly $329 million depending on the source. North American plasma disposable volumes were already running up in the mid-20% range organically in the most recent quarter. CSL’s return layering onto that base is what Wall Street is repricing.

Analyst Reaction

BTIG raised its price target from $110 to $130, lifting its valuation multiple to approximately 21 times forward earnings from 18.5 times. The firm said it is not yet embedding any CSL revenue into its model, pending detail on the rollout cadence. That is a meaningful disclosure: the target move is primarily a multiple re-rating, not a revenue upgrade. If CSL delivers, the earnings revisions come separately, on the November 5 earnings call.

Citi had already upgraded HAE to Buy in September, lifting its target from $92 to $123, and estimated that each 10% recovery of CSL business could add roughly $0.13 to annual earnings per share.

Risks Worth Noting

The agreement is non-exclusive and carries no minimum purchase commitments. CSL can still change the scope and timing. Haemonetics itself flagged that implementation details remain to be determined. The stock now trades at a forward multiple above its five-year average of roughly 19 times, meaning there is less room for disappointment than there was a week ago. A slower-than-expected rollout or any renegotiation of scope could unwind a portion of Thursday’s gains quickly.

The Bigger Picture

What Thursday confirmed is that Haemonetics’ NexSys platform, particularly with Persona PLUS, is differentiated enough for the world’s largest plasma company to switch suppliers twice. CSL left, ran Terumo’s system for several years, and is coming back. That is a meaningful product validation. For investors, the disposable revenue model tied to 300-plus high-volume collection centers is the kind of recurring base that commands a durable premium. How fast CSL installs the hardware determines when that premium is earned, not just assumed.

The November earnings call is the first real checkpoint. Management has signaled it will provide a more concrete financial impact estimate then. Until that number arrives, HAE is a company whose largest customer just came home, with the revenue still to be confirmed.